• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在 HBsAg 血清学清除的慢性乙型肝炎患者中,使用高度敏感的 iTACT 检测方法检测 HBcrAg 和 HBsAg 的动力学。

Kinetics of HBcrAg and HBsAg using highly sensitive iTACT assays in chronic hepatitis B patients with HBsAg seroclearance.

机构信息

Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

Department of Gastroenterology and Hepatology, Kumamoto University, Kumamoto, Japan.

出版信息

J Med Virol. 2023 Sep;95(9):e29109. doi: 10.1002/jmv.29109.

DOI:10.1002/jmv.29109
PMID:37721406
Abstract

Two novel assays have been developed, iTACT-hepatitis B core-related antigen (iTACT-HBcrAg) and iTACT-hepatitis B surface antigen (iTACT-HBsAg) assays. We investigated the longitudinal profiles of iTACT-HBcrAg- and -HBsAg in patients with HBsAg seroclearance (SC) (<0.05 IU/mL). This study comprises 60 HBV-infected patients with HBsAg SC, 27 in chronic hepatitis/liver cirrhosis (CH/LC) group and 33 in inactive carrier (IC) group. Longitudinal profiles of iTACT-HBcrAg and -HBsAg were examined using stored serum samples. The median period from HBsAg SC to iTACT-HBcrAg loss or to the last observation was longer in the CH/LC group than the IC group (39 vs. -3 months, p = 0.004), but this tendency was not observed in that by iTACT-HBsAg. Comparing the times of iTACT-HBcrAg and -HBsAg loss, the rate of patients who lost HBcrAg first was significantly higher in the IC group (p = 0.008). The cumulative incidence rate of iTACT-HBcrAg loss after HBsAg SC was higher in the IC group that the CH/LC group (p = 0.002). Patients in the CH/LC group had higher rates of detectable iTACT-HBcrAg than those in the IC group after HBsAg SC, suggesting that the presence of HBcrAg possibly contribute to the progression of chronic hepatitis B.

摘要

两种新的检测方法已经开发出来,即 iTACT-乙型肝炎核心相关抗原 (iTACT-HBcrAg) 和 iTACT-乙型肝炎表面抗原 (iTACT-HBsAg) 检测方法。我们研究了 HBsAg 血清学清除(<0.05IU/mL)患者的 iTACT-HBcrAg 和 -HBsAg 的纵向特征。这项研究包括 60 名 HBV 感染患者,其中 27 名处于慢性肝炎/肝硬化(CH/LC)组,33 名处于非活动携带(IC)组。使用存储的血清样本检测 iTACT-HBcrAg 和 -HBsAg 的纵向特征。HBsAg 清除后至 iTACT-HBcrAg 丢失或最后一次观察的中位时间在 CH/LC 组比 IC 组更长(39 比-3 个月,p=0.004),但这种趋势在 iTACT-HBsAg 中并未观察到。比较 iTACT-HBcrAg 和 -HBsAg 丢失的时间,IC 组中首先丢失 HBcrAg 的患者比例显著更高(p=0.008)。HBsAg 清除后 iTACT-HBcrAg 丢失的累积发生率在 IC 组高于 CH/LC 组(p=0.002)。HBsAg 清除后,CH/LC 组患者的 iTACT-HBcrAg 可检测率高于 IC 组,表明 HBcrAg 的存在可能导致慢性乙型肝炎的进展。

相似文献

1
Kinetics of HBcrAg and HBsAg using highly sensitive iTACT assays in chronic hepatitis B patients with HBsAg seroclearance.在 HBsAg 血清学清除的慢性乙型肝炎患者中,使用高度敏感的 iTACT 检测方法检测 HBcrAg 和 HBsAg 的动力学。
J Med Virol. 2023 Sep;95(9):e29109. doi: 10.1002/jmv.29109.
2
A longitudinal study to detect hepatitis B surface and core-related antigens in chronic hepatitis B patients with hepatitis B surface antigen seroclearance using highly sensitive assays.一项使用高敏检测试剂检测乙型肝炎表面抗原血清学转换的慢性乙型肝炎患者乙型肝炎表面抗原和核心相关抗原的纵向研究。
J Clin Virol. 2023 Mar;160:105375. doi: 10.1016/j.jcv.2022.105375. Epub 2022 Dec 23.
3
Clinical performance of Circulating HBV RNA and iTACT-HBcrAg Assays in HBeAg-negative and HBsAg-cleared Chronic Hepatitis B Patients.Circulating HBV RNA 和 iTACT-HBcrAg 检测在 HBeAg 阴性和 HBsAg 清除的慢性乙型肝炎患者中的临床性能。
J Med Virol. 2024 Jul;96(7):e29816. doi: 10.1002/jmv.29816.
4
Potential of ultra-highly sensitive immunoassays for hepatitis B surface and core-related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.乙肝表面抗原血清清除后发生或未发生肝细胞癌的患者中乙肝表面和核心相关抗原超高度灵敏免疫测定的潜力
Hepatol Res. 2021 Apr;51(4):426-435. doi: 10.1111/hepr.13602. Epub 2021 Mar 6.
5
Clinical usefulness of a novel high-sensitivity hepatitis B core-related antigen assay to determine the initiation of treatment for HBV reactivation.新型高敏乙型肝炎核心相关抗原检测在确定乙型肝炎病毒再激活治疗中的临床应用。
J Gastroenterol. 2022 Jul;57(7):486-494. doi: 10.1007/s00535-022-01872-w. Epub 2022 Apr 28.
6
Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B.慢性乙型肝炎自然史中的线性乙型肝炎表面抗原和乙型肝炎核心相关抗原。
Clin Microbiol Infect. 2014 Nov;20(11):1173-80. doi: 10.1111/1469-0691.12739. Epub 2014 Jul 29.
7
Management of hepatitis B virus (HBV) reactivation in patients with resolved HBV infection based on a highly sensitive HB core-related antigen assay.基于高灵敏度乙肝核心相关抗原检测的乙肝病毒(HBV)感染已缓解患者的HBV再激活管理
Hepatol Res. 2022 Sep;52(9):745-753. doi: 10.1111/hepr.13761. Epub 2022 Mar 9.
8
Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation.一种新型高灵敏度乙肝核心相关抗原检测法在慢性乙型肝炎管理及乙肝病毒再激活中的临床疗效
J Hepatol. 2021 Aug;75(2):302-310. doi: 10.1016/j.jhep.2021.02.017. Epub 2021 Mar 21.
9
Low Hepatitis B Core-Related Antigen Levels Correlate Higher Spontaneous Seroclearance of Hepatitis B Surface Antigen in Chronic Hepatitis B Patients With High Hepatitis B Surface Antigen Levels.低乙型肝炎核心相关抗原水平与高乙型肝炎表面抗原水平的慢性乙型肝炎患者的乙型肝炎表面抗原自发血清学清除率相关。
Gastroenterology. 2023 Apr;164(4):669-679.e6. doi: 10.1053/j.gastro.2023.01.005. Epub 2023 Jan 13.
10
Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy.乙型肝炎核心相关抗原:一种新型有前途的替代生物标志物,可指导乙型肝炎病毒治疗。
Clin Mol Hepatol. 2023 Oct;29(4):851-868. doi: 10.3350/cmh.2022.0434. Epub 2023 Mar 9.

引用本文的文献

1
Virological markers for clinical trials in chronic viral hepatitis.慢性病毒性肝炎临床试验的病毒学标志物
JHEP Rep. 2024 Sep 7;6(11):101214. doi: 10.1016/j.jhepr.2024.101214. eCollection 2024 Nov.
2
Two Concepts of Hepatitis B Core-Related Antigen Assay: A Highly Sensitive and Rapid Assay or an Effective Tool for Widespread Screening.两种乙型肝炎核心相关抗原检测概念:高灵敏度和快速检测,还是广泛筛查的有效工具。
Viruses. 2024 May 26;16(6):848. doi: 10.3390/v16060848.
3
Quantitative hepatitis B core antibody and quantitative hepatitis B surface antigen: Novel viral biomarkers for chronic hepatitis B management.
乙型肝炎核心抗体定量和乙型肝炎表面抗原定量:用于慢性乙型肝炎管理的新型病毒生物标志物。
World J Hepatol. 2024 Apr 27;16(4):550-565. doi: 10.4254/wjh.v16.i4.550.